维吾尔族和汉族多发性骨髓瘤患者血清白介素6水平测定及其临床意义

Detection of Serum Interleukin-6 Level in Patients with Multiple Myeloma of Vighur Nationality and Han Nationality and Its Clinical Significance

为了研究维吾尔族、汉族多发性骨髓瘤(MM)患者血清白介素6(IL-6)水平差异及检测的临床意义,采用双抗体夹心ELISA技术检测80例MM患者(33例维吾尔族、47例汉族)和30名正常人血清IL-6活性。结果发现:维吾尔族与汉族MM患者间血清IL-6水平存在显著差异(P<0.01),MM患者血清IL-6水平明显高于正常人组(P<0.01),Ⅱ、Ⅲ期MM患者血清IL-6水平明显高于I期患者(P<0.05)。结论:维吾尔族与汉族MM患者血清IL-6水平存在显著差异性。血清IL-6水平可以作为判断MM患者病情严重程度、预后的指标之一,也是观察疗效、指导临床用药的综合多参数之一。

To investigate the difference of serum interleukin-6 level in the patients with multiple myeloma （MM） of Vighur nationality and Han nationality and its clinical significance, the activity of serum interleukin-6 was detected in 80 patients with MM （33 Vighur patients, 47 Han patients） and 30 normal subjects as control by using sandwich ELISA with double antibody. The results showed that there was significant difference in serum interleukin-6 level between Vighur patients and Han patients （ P 〈 0.01 ）. The serum interleukin-6 level of patients with multiple myeloma was significantly higher than that of nomal control （P 〈 0.01 ）, The serum interleukin-6 level of MM patients in second and third stage were also signifivantly higher than that of patients in first stage （ P 〈 0.05 ）. It is concluded that there was significant difference in the serum interleukin-6 level between Vighur patients and Han patients. The serum interleukin-6 level can be considered as one of indexes to judge the patient severity and the prognosis, also as one of comprehensive multiparameters to evaluate the curative efficiency and guide the clinical application of drugs.